TheraRadar
Clinical-Stage Companies / Sinotau Pharmaceutical Group

Sinotau Pharmaceutical Group

Pre-Approval PRO BETA
13
Total Trials
4
Phase 3
6
Phase 2
7
Recruiting
138
Score

Pipeline by Phase

Phase 3
4
Phase 2
6
Phase 1
5

Therapeutic Focus

Coronary Artery Disease (CAD) Prostate Cancer Alzheimer Disease Coronary Artery Disease(CAD) Ischemic Cardiomyopathy

Clinical Trials (13)

NCT07439133 Phase 3 RECRUITING

Comparison of Diagnostic Accuracy Between XTR004 PET MPI and the Composite Index of Quantitative Coronary Angiography (QCA) and Fractional Flow Reserve (FFR)

Started: 11/14/2025

NCT07115238 Phase 3 RECRUITING

Analysis of 18F-XTR006 PET Imaging in Cognitively Normal Subjects, and Patients With MCI and AD

Started: 11/20/2024

NCT05459844 Phase 3 ACTIVE NOT RECRUITING

A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs

Started: 8/31/2022

NCT07443696 Phase 2 RECRUITING

PET Myocardial Fatty-acid Metabolic Imaging With XTR003 Injection and 18F-FDG to Assess Myocardial Viability in Ischemic Cardiomyopathy

Started: 12/18/2025

NCT07187895 Phase 2 TERMINATED

Comparative Imaging of XTR004 PET and MIBI SPECT in Borderline Coronary Stenosis

Started: 12/19/2024

NCT06398444 Phase 2 ACTIVE NOT RECRUITING

A Clinical Study of Lutetium[177Lu] Oxodotreotide Injection in Patients With Advanced Neuroendocrine Neoplasms

Started: 6/11/2024

NCT05885841 Phase 2 COMPLETED

Evaluation of XTR004 as a Novel 18F-labeled PET MPI Tracer in Diagnosis of Known or Suspected CAD

Started: 2/15/2022

NCT05885854 Phase 2 COMPLETED

XTR003 PET Radiotracer for the Detection of Viable Myocardium

Started: 12/15/2021

NCT07149831 Phase 1 RECRUITING

A Clinical Trial Evaluating the Safety and Tolerability, Biodistribution and Radiation Dosimetry, and Pharmacokinetics of Flotufolastat F-18 Injection in Healthy Chinese Adults

Started: 6/7/2025

NCT06081686 Phase 1 RECRUITING

Study of [177Lu] Lu-XT033 Injection in Patients With Metastatic Prostate Cancer

Started: 9/13/2023

NCT06151795 Phase 1 COMPLETED

A Study to Evaluate XTR006 in Chinese Volunteers

Started: 6/12/2023

NCT05195879 Phase 1 COMPLETED

A Study of XTR004 Radiotracer in Healthy Volunteers

Started: 3/23/2021

NCT05136391 Phase 1 COMPLETED

A Phase I Study to Evaluate XTR003 in Healthy Chinese Volunteers

Started: 3/29/2021

Drug Candidates

XTR004 Fasting XTR003/¹⁸F-FDG PET myocardial metabolic imaging Glucose-loaded ¹⁸F-FDG PET Myocardial Metabolic Imaging Lutetium[177Lu] Oxodotreotide Injection Octreotide LAR Flotufolastat F-18 Injection XTR006 Phase I:[177Lu]Lu-XT033 Injection Phase II:[177Lu]Lu-XT033 Injection XTR003
Activity Status: Active
Last Trial Started: 12/18/2025
Last Trial Ended: 3/5/2025
Trials (12 months): 3
Completed Trials: 5
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.